Pharmacogenomic Analysis in Multiple Sclerosis This issue of Neura features a review on pharmacogenomics in multiple sclerosis (MS), an area whose goal is to be able to predict a patient's response to disease-modifying therapy (DMT) and perhaps lead to personalized medicine in MS. Other articles include a review on the therapeutic effects of lithium in amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD) and an article and patient tear-out page on adherence to DMT. A special NeurAlert section provides information on a recent alert from the Food and Drug Administration (FDA) on cardiac management of patients with MS receiving mitoxantrone. |
 Hot Topic: Pharmacogenomic Analysis in Multiple Sclerosis
A reliable, early predictor of individual responses to MS therapies could allow appropriate tailoring of care. Read this article to learn more about the relevant research that one day may lead to personalized treatment for MS.
Lithium in Amyotrophic Lateral Sclerosis and Alzheimer’s Disease
In various experimental models of neurodegenerative diseases, lithium has been shown to have neuroprotective properties. In the clinical setting, study results suggest lithium has beneficial effects in ALS and AD. This article presents a review.
Adherence to Self-Injectable Therapy in MS
Most of the current DMTs for relapsing-remitting MS are injectable. However, the indefinitely long-term adherence to these therapies necessary for maximum benefit is fraught with difficulties. Featured here are an overview of the problems involved in self-injectable therapy and possible solutions.
NeurAlert: New FDA Advisory for Management of Mitoxantrone Therapy in Patients with MS
On July 29, 2008, the FDA issued an updated alert that recommends long-term monitoring of patients receiving mitoxantrone. This special NeurAlert section has reprinted the parts relevant to the monitoring of patients with MS.
**Online Exclusive**
Summaries of recently published articles are available only at Neura.net. Click to read them.
|
